Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.46 |
| ▸ | KDR | P35968 | 13/20 | 0.43 |
| ▸ | MST1R | Q04912 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294359 | 0.91 | MET (0.52) | METKDRMST1RFLT1FLT4 | |
| SCHEMBL4296624 | 0.90 | MET (0.44) | METKDRMST1RNPC1RAB9A | |
| SCHEMBL4299938 | 0.86 | MET (0.45) | METKDRMST1RNPC1RAB9A | |
| SCHEMBL4298762 | 0.85 | MET (0.50) | METKDRMST1RFLT1FLT4 | |
| SCHEMBL4296630 | 0.84 | MET (0.56) | METKDRMST1RFLT1FLT4 | |
| SCHEMBL13663033 | 0.82 | MET (0.60) | METKDRMST1RNPC1RAB9A | |
| SCHEMBL4298150 | 0.80 | MET (0.51) | METKDRMST1RFLT1FLT4 | |
| SCHEMBL13663026 | 0.78 | MET (0.52) | METKDRMST1RNPC1RAB9A | |
| SCHEMBL13663036 | 0.77 | MET (0.53) | METKDRMST1RNPC1RAB9A | |
| SCHEMBL13663034 | 0.75 | MET (0.74) | METKDRMST1RFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | claimed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1870414-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | Kirin Pharma Kabushiki Kaisha (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | MET, ABL1, RET | MET 1/4885KDR 39/4885MST1R 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.